Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.15 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.72 | 27.28 | 28.48 | 3184.91 | 65.82 | 591.17 | 833.27 | 384.06 | 473.59 | 495.67 | 426.51 | 351.04 | 276.08 | 319.88 | 229.56 | 420.99 | 513.17 | 613.14 | 822.38 | 700.40 | 603.74 |
| — | -95.4% | -96.6% | +729.3% | -86.1% | +19.3% | +95.4% | +9.4% | +71.5% | +55.0% | +85.8% | -16.6% | -46.2% | -47.8% | -72.1% | -39.9% | -15.0% | -21.8% | -38.9% | -23.6% | -6.2% | |
| P/B Ratio | 0.26 | 2.27 | 2.37 | 231.24 | 4.78 | 57.08 | 80.46 | 50.59 | 62.38 | 126.37 | 108.73 | 34.86 | 41.35 | 36.48 | 21.19 | 74.18 | 56.37 | 50.58 | 56.08 | 39.74 | 64.94 |
| — | -96.0% | -97.1% | +357.1% | -92.3% | -54.8% | -26.0% | +45.1% | +50.9% | +246.4% | +413.1% | -53.0% | -26.7% | -27.9% | -62.2% | +86.7% | -13.2% | -74.5% | -50.2% | -56.1% | +14.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | 659.97 | — | 315.34 | — | 926.53 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -28.8% | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -2456.8% | -2316.8% | -2316.8% | -2488.7% | -2488.7% | -2424.8% | -2424.8% | -1127.4% | -1127.4% | -1295.6% | -1295.6% | -1183.2% | -951.5% | -910.2% | -1383.7% | -1565.0% | -1261.3% | -1014.7% | -1218.5% | -1974.5% | -1398.4% |
| — | +4.5% | +4.5% | -120.7% | -120.7% | -87.2% | -87.2% | +4.7% | -18.5% | -42.3% | +6.4% | +24.4% | +24.6% | +10.3% | -13.6% | +20.7% | +9.8% | +19.0% | +16.9% | +16.6% | -19.0% | |
| Net Margin | -2426.7% | -2277.7% | -2277.7% | -2439.4% | -2439.4% | -2413.9% | -2413.9% | -1095.8% | -1095.8% | -1252.2% | -1252.2% | -1065.8% | -899.0% | -852.0% | -1218.4% | -1500.0% | -1196.6% | -1192.6% | -1249.8% | -2018.6% | -1354.6% |
| — | +5.6% | +5.6% | -122.6% | -122.6% | -92.8% | -92.8% | -2.8% | -21.9% | -47.0% | -2.8% | +28.9% | +24.9% | +28.6% | +2.5% | +25.7% | +11.7% | +7.4% | +1.5% | +16.7% | -11.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -179.7% | -47.4% | -44.0% | -44.3% | -50.7% | -58.3% | -50.7% | -36.1% | -49.6% | -79.8% | -45.4% | -28.8% | -29.1% | -21.7% | -36.8% | -49.7% | -28.2% | -22.2% | -19.4% | -34.7% | -51.2% |
| — | +18.7% | +13.1% | -22.7% | -2.2% | +27.0% | -11.7% | -25.4% | -70.3% | -267.2% | -23.2% | +42.0% | -3.2% | +2.1% | -89.8% | -43.0% | +44.9% | +62.0% | +32.1% | +25.4% | -85.8% | |
| ROA | -106.3% | -28.6% | -26.2% | -26.0% | -28.7% | -31.6% | -29.0% | -21.5% | -26.1% | -33.4% | -24.9% | -17.2% | -17.4% | -13.6% | -21.0% | -26.9% | -17.8% | -14.9% | -13.4% | -23.6% | -28.0% |
| — | +9.6% | +9.6% | -21.0% | -10.2% | +5.5% | -16.4% | -24.7% | -49.5% | -145.3% | -18.6% | +35.8% | +1.9% | +8.8% | -55.9% | -13.9% | +36.4% | +48.0% | +20.3% | +25.8% | -41.8% | |
| ROIC | -1769.8% | -91.5% | -170.9% | -1403.3% | — | — | — | -211.7% | — | — | — | -70.4% | -51.9% | -24.9% | -46.1% | -86.7% | -32.1% | -20.8% | -22.4% | -44.0% | -79.4% |
| — | — | — | -563.0% | — | — | — | -200.7% | — | — | — | +18.9% | -62.1% | -19.3% | -105.8% | -97.4% | +59.7% | +67.2% | +84.5% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -53.1% | -53.1% | -33.6% | -33.6% | -6.4% | -6.4% | +198.6% | +96.4% | +139.5% | +306.8% | -53.8% | -2.2% | +9.2% | -37.7% | +60.8% | -8.8% | -48.8% | +16.7% | -21.8% | +112.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.46 | 3.60 | 3.60 | 3.46 | 3.46 | 3.60 | 3.60 | 4.38 | 4.38 | 2.93 | 2.93 | 4.90 | 4.10 | 4.89 | 4.63 | 3.66 | 4.49 | 6.78 | 6.09 | 7.35 | 6.72 |
| — | +0.0% | +0.0% | -21.0% | -21.0% | +22.6% | +22.6% | -10.8% | +6.7% | -40.0% | -36.6% | +34.0% | -8.7% | -27.9% | -24.0% | -50.2% | -33.2% | +67.3% | -0.7% | -0.8% | -7.6% | |
| Quick Ratio | 3.46 | 3.60 | 3.60 | 3.46 | 3.46 | 3.60 | 3.60 | 4.38 | 4.38 | 2.93 | 2.93 | 4.90 | 4.10 | 4.89 | 4.63 | 3.66 | 4.49 | 6.78 | 6.09 | 7.35 | 7.10 |
| — | +0.0% | +0.0% | -21.0% | -21.0% | +22.6% | +22.6% | -10.8% | +6.7% | -40.0% | -36.6% | +34.0% | -8.7% | -27.9% | -24.0% | -50.2% | -36.7% | +41.5% | -8.1% | -0.8% | -20.3% | |
| Interest Coverage | -710.72 | — | — | — | — | — | — | — | — | — | — | -131.00 | -621.67 | — | — | -192.69 | — | -17.11 | -37.03 | -12.79 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CANF stock.
Can-Fite BioPharma Ltd.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Can-Fite BioPharma Ltd.'s current operating margin is -2456.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Can-Fite BioPharma Ltd.'s business trajectory between earnings reports.